Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021-2024).

IF 4.6 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI:10.1080/13543776.2025.2515882

Yung-Fong Tsai, Shun-Chin Yang, Tsong-Long Hwang

{"title":"Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021-2024).","authors":"Yung-Fong Tsai, Shun-Chin Yang, Tsong-Long Hwang","doi":"10.1080/13543776.2025.2515882","DOIUrl":null,"url":null,"abstract":"Introduction: Formyl peptide receptors (FPRs) belong to the family of class A G-protein-coupled receptors that are important for immune modulation and inflammation and are emerging as potential therapeutic targets for several inflammatory diseases. FPRs have shown therapeutic roles in the management of cardiovascular diseases, neuroinflammation, and cancer. Biased agonists are an active topic in the further revisions that encompass the utilization of a definite subset of signaling pathways to improve therapeutic maladies, in parallel with reducing the negative effects.Areas covered: This review surveys the modulators of FPR1 and FPR2 that have been published in patents from 2021 to 2024, to summarize the categorization of agonists and antagonists and discuss their possible clinical uses. A targeted patent search was performed using the Taiwan Patent GO Showcases database (https://tiponet.tipo.gov.tw/gpss/).Expert opinion: We examine newly disclosed patents concerning FPR modulators, with all specified compounds classified as either FPR1 or FPR2 modulators. Receptor cross-reactivity, ligand promiscuity, and receptor variations across species are challenges encountered during drug formulation. Further research into different types of biased agonists and the synthesis of potent and selective ligands is essential to overcome these obstacles and facilitate the eventual therapeutic use of biased signaling in inflammation and diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"839-857"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2025.2515882","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Formyl peptide receptors (FPRs) belong to the family of class A G-protein-coupled receptors that are important for immune modulation and inflammation and are emerging as potential therapeutic targets for several inflammatory diseases. FPRs have shown therapeutic roles in the management of cardiovascular diseases, neuroinflammation, and cancer. Biased agonists are an active topic in the further revisions that encompass the utilization of a definite subset of signaling pathways to improve therapeutic maladies, in parallel with reducing the negative effects.

Areas covered: This review surveys the modulators of FPR1 and FPR2 that have been published in patents from 2021 to 2024, to summarize the categorization of agonists and antagonists and discuss their possible clinical uses. A targeted patent search was performed using the Taiwan Patent GO Showcases database (https://tiponet.tipo.gov.tw/gpss/).

Expert opinion: We examine newly disclosed patents concerning FPR modulators, with all specified compounds classified as either FPR1 or FPR2 modulators. Receptor cross-reactivity, ligand promiscuity, and receptor variations across species are challenges encountered during drug formulation. Further research into different types of biased agonists and the synthesis of potent and selective ligands is essential to overcome these obstacles and facilitate the eventual therapeutic use of biased signaling in inflammation and diseases.

查看原文本刊更多论文

甲酰基肽受体调节剂：专利审查和炎症疾病的潜在应用（2021-2024）。

甲酰基肽受体（FPRs）属于A类g蛋白偶联受体家族，在免疫调节和炎症中起重要作用，并且正在成为几种炎症性疾病的潜在治疗靶点。FPRs已在心血管疾病、神经炎症和癌症的治疗中显示出治疗作用。在进一步的修订中，偏倚激动剂是一个活跃的话题，它包括利用信号通路的一个确定子集来改善治疗性疾病，同时减少负面影响。涵盖领域：本综述调查了从2021年到2024年已发表专利的FPR1和FPR2调节剂，总结了激动剂和拮抗剂的分类，并讨论了它们可能的临床应用。使用台湾专利GO展示数据库（https://tiponet.tipo.gov.tw/gpss/）.Expert)进行了有针对性的专利检索：我们审查了有关FPR调节剂的新公开专利，所有指定的化合物都分类为FPR1或FPR2调节剂。受体交叉反应性、配体混杂性和不同物种的受体变异是药物配制过程中遇到的挑战。进一步研究不同类型的偏倚激动剂以及强效和选择性配体的合成对于克服这些障碍和促进最终在炎症和疾病中使用偏倚信号治疗至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.